[Bortezomib-induced acute neutrophilic dermatosis]. / Dermatose neutrophilique aiguë induite par le bortezomib.
Ann Dermatol Venereol
; 136(5): 443-6, 2009 May.
Article
em Fr
| MEDLINE
| ID: mdl-19442803
ABSTRACT
INTRODUCTION:
Bortezomid is a potent proteasome inhibitor used in patients with relapsing or refractory multiple myeloma and provides a 35% response with a median duration of response of 12 months. Numerous adverse effects are known, mainly comprising haematological and neurological complications. A wide variety of cutaneous complications have also been described in 10 to 20% of patients. CASE REPORT We report a case of bortezomib-induced Sweet syndrome. The diagnostic criteria required for drug-induced Sweet syndrome were present.DISCUSSION:
The importance of this description is that this induced Sweet syndrome may not necessarily require cessation of bortezomid since administration of corticosteroids prevents its recurrence.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirazinas
/
Dermatopatias
/
Ácidos Borônicos
/
Mieloma Múltiplo
/
Neutrófilos
/
Antineoplásicos
Limite:
Aged
/
Humans
/
Male
Idioma:
Fr
Revista:
Ann Dermatol Venereol
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
França